Alan Swaisland
Overview
Explore the profile of Alan Swaisland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gross M, Leichman L, Lowe E, Swaisland A, Agus D
Cancer Chemother Pharmacol
. 2011 Oct;
69(1):273-80.
PMID: 22002543
Purpose: Previous studies established the safety of continuous gefitinib 250 or 500 mg daily. It was postulated that a higher dose may have increased efficacy by inhibiting signaling in both...
2.
Horak J, White J, Harris A, Verrill M, Carmichael J, Holt A, et al.
Cancer Chemother Pharmacol
. 2011 Apr;
68(6):1485-95.
PMID: 21487718
Purpose: We investigated whether the pharmacokinetics and tolerability of gefitinib were altered in patients with hepatic impairment due to cirrhosis or hepatic metastases in two open, parallel-group, multicenter studies. Methods:...
3.
Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz H, et al.
Clin Cancer Res
. 2010 Sep;
16(19):4876-83.
PMID: 20805299
Purpose: This dose-escalation study evaluated the safety, tolerability, and pharmacokinetics (PK) of the oral Src inhibitor saracatinib (AZD0530) in patients with advanced solid malignancies. Tumor biopsy samples were taken to...
4.
Dalton R, Chetty R, Stuart M, Iacona R, Swaisland A
Anticancer Res
. 2010 Aug;
30(7):2935-42.
PMID: 20683035
Background: Saracatinib (AZD0530), a potent Src inhibitor, is a subject of current evaluation as an anticancer therapy. Increased plasma creatinine levels have previously been observed after saracatinib administration in healthy...
5.
Hannon R, Clack G, Rimmer M, Swaisland A, Lockton J, Finkelman R, et al.
J Bone Miner Res
. 2009 Sep;
25(3):463-71.
PMID: 19775203
Src is a nonreceptor tyrosine kinase thought to be essential for osteoclast function and bone resorption. We investigated the effect of the orally available Src inhibitor saracatinib (AZD0530) on bone...
6.
Chhun S, Verstuyft C, Rizzo-Padoin N, Simoneau G, Becquemont L, Peretti I, et al.
Br J Clin Pharmacol
. 2009 Aug;
68(2):226-37.
PMID: 19694743
Aims: We aimed to describe the pharmacokinetic interaction between phenytoin, a potent CYP3A4 and P-glycoprotein (P-gp) (ABCB1) inducer, and gefitinib, a CYP3A4, CYP2D6 and P-gp substrate. Methods: An open-label, randomized,...
7.
Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies B, Wilkinson R, et al.
Anticancer Drugs
. 2009 Aug;
20(10):856-66.
PMID: 19657272
Two small-molecule epidermal growth factor receptor tyrosine kinase inhibitors, gefitinib and erlotinib, have been approved for the treatment of non-small-cell lung cancer. Here, we compare the pharmacology and pharmacokinetics of...
8.
Stewart J, Cohen E, Licitra L, Van Herpen C, Khorprasert C, Soulieres D, et al.
J Clin Oncol
. 2009 Mar;
27(11):1864-71.
PMID: 19289630
Purpose: To compare survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with gefitinib 250 or 500 mg/day or standard methotrexate. Patients...